Caerus Investment Advisors Adds Regeneron Pharmaceuticals to Portfolio

New position in biotech company valued at $747,000

Mar. 18, 2026 at 8:52am

Got story updates? Submit your updates here. ›

Caerus Investment Advisors LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to a recent SEC filing. The fund acquired 1,329 shares of the biopharmaceutical company's stock, valued at approximately $747,000.

Why it matters

Regeneron Pharmaceuticals is a prominent biotech company known for its innovative drug discovery technologies and pipeline of biologic therapies. The addition of Regeneron to Caerus Investment Advisors' portfolio signals the firm's confidence in the company's growth potential and future prospects.

The details

According to the filing, Caerus Investment Advisors acquired the 1,329 shares of Regeneron Pharmaceuticals during the third quarter. The position is valued at approximately $747,000. Several other large investors have also made changes to their Regeneron holdings in recent quarters, with some increasing their positions and others establishing new stakes.

  • Caerus Investment Advisors acquired the Regeneron position during the third quarter.

The players

Caerus Investment Advisors LLC

An investment management firm that acquired a new position in Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The addition of Regeneron Pharmaceuticals to Caerus Investment Advisors' portfolio reflects the firm's confidence in the biotech company's growth prospects and innovative drug pipeline. This move aligns with broader investor interest in the life sciences sector and Regeneron's position as a leading player in the industry.